1st SMI Highly Potent Active Pharmaceutical Ingredients Conference 2017 London

  • Conference Call
  • SMi Group is hold­ing it’s 1st Highly Potent Active Phar­ma­ceu­ti­cal Ingre­di­ents Con­fer­ence on May 2223, 2017 in Lon­don, UK at the Copthorne Tara Hotel and is seek­ing your involvement.

    Overview

    The global mar­ket for Highly Potent Active Phar­ma­ceu­ti­cal Ingre­di­ents is cur­rently on a growth fast track, largely dri­ven by its major use in oncol­ogy for can­cer treat­ment and more often in the form of ADCs. Over a quar­ter of drugs world­wide now con­tain HPA­PIs, as they have proven to be more effec­tive than other APIs.

    How­ever, work­ing with APIs high in potency and cyto­tox­i­c­ity comes with many reg­u­la­tions and require­ments, and presents phar­ma­ceu­ti­cal com­pa­nies with chal­lenges such as han­dling, con­tain­ment, cost and secu­rity questions.

    The inau­gural Highly Potent Active Phar­ma­ceu­ti­cal Ingre­di­ents con­fer­ence fea­tures key speak­ers of the indus­try pre­sent­ing chal­lenges, issues, inno­va­tion and new devel­op­ments in var­i­ous areas of HPAPI pro­duc­tion, devel­op­ment and manufacturing.

    Hear about new inno­v­a­tive con­tain­ment risk assess­ment tools and con­tain­ment strate­gies when han­dling HPAPI prod­ucts. Guid­ance for the eval­u­a­tion and man­age­ment of cross-​contamination will be addressed, as well as newest con­trol strate­gies and solu­tions. Phar­ma­ceu­ti­cal com­pa­nies will be pre­sent­ing their approaches to scale-​up processes and will be dis­cussing man­u­fac­tur­ing facil­ity designs and require­ments, also intro­duc­ing flex­i­ble facil­i­ties. Learn more about CMO selec­tion strate­gies and how to improve infor­ma­tion and tech­nol­ogy transfer.

    This con­fer­ence will cover many impor­tant and in-​demand aspects of the HPAPI indus­try, cre­at­ing a net­work­ing plat­form for indus­try pro­fes­sion­als and key play­ers to share their knowl­edge and find inno­v­a­tive new solutions.

    Speakers

    • Alessan­dro Briggo – Prin­ci­pal Sci­en­tist, Tox­i­col­ogy Project Leader, Roche
    • Alexan­der Flück­iger – Chief Occu­pa­tional Health Offi­cer, Roche
    • Aurore Perzyna – Head, Pro­duc­tion Plant, Oril Industries
    • Clau­dia Sehner – Prin­ci­pal Sci­en­tist, Occu­pa­tional Tox­i­col­ogy, Boehringer Ingelheim
    • Dean Cal­houn – Pres­i­dent /​CEO, Affy­gility Solutions
    • Eber­hard Ramisch – Global Head Pro­ject­man­age­ment Phar­ma­ceu­ti­cal Ingre­di­ents, Her­aeus GmbH & Co. KG
    • Fabio Zenobi – EHS Direc­tor, BSP Pharmaceuticals
    • Gre­gory Sow­ell – Prin­ci­pal Sci­en­tific Man­ager, Small Mol­e­cule Process Chem­istry, Genentech
    • Gwydion Churchill – Asso­ciate Direc­tor of Chem­istry, Antibi­otics Busi­ness Unit, AstraZeneca
    • Ildiko Ziegler – Dis­tin­guished Val­i­da­tion Expert, Gedeon Richter Plc.
    • Jack Brown – Senior Prin­ci­pal Sci­en­tist, Boehringer Ingel­heim Phar­ma­ceu­ti­cals, Inc.
    • James Evans – Vice Pres­i­dent CMC, NuCana Bio­Med Limited
    • Jason Hamm – Direc­tor — Chem­i­cal Devel­op­ment Oper­a­tions, Bristol-​Myers Squibb
    • Jhon Esco­bar – Oper­a­tions /​Sup­ply Chain Man­ager, Teva API
    • Michael Groan­ing – Direc­tor, Strate­gic Devel­op­ment, Endocyte
    • Richard Denk – Head Sales Con­tain­ment, SKAN AG
    • Robert Suss­man – Prin­ci­pal Tox­i­col­o­gist and Man­ag­ing Prin­ci­pal, East­ern Oper­a­tions, SafeBridge Con­sul­tants LLC
    • Shay Carmi – OPEX QC Work­stream Leader — Teva Tech Site, Teva API
    • Yaakov Machlav – Process Safety Man­ager, Teva Phar­ma­ceu­ti­cals Ltd

    Con­fer­ence Topics

    • Basic under­stand­ing of occu­pa­tional health risk assess­ments: haz­ard and exposure
    • Case study 1: steroid hor­monal API production
    • Case study 2: man­u­fac­tur­ing par­enteral cyto­toxic products
    • Cat­e­gories of con­cern” (cyto­tox­ics, hor­mones, steroids) are often referred to, but rarely defined for APIs requir­ing seg­re­ga­tion or ded­i­ca­tion in manufacturing
    • Chal­lenges with HPA­PIs are very unique, in that there is typ­i­cally lim­ited data on.
    • Char­ac­ter­is­tics of these cat­e­gories are dis­cussed to iden­tify and pri­or­i­tize com­pounds requir­ing spe­cial attention
    • Com­plex­ity of cross con­t­a­m­i­na­tion risk and tech­ni­cal mea­sures at pro­duc­tion areas
    • Com­pli­ance with worker health reg­u­la­tions in an envi­ron­ment where no-​one complies
    • Con­tain­ment from the PDE/​OEL to Life Cycle
    • Con­tain­ment Risk Man­age­ment of HP drug sub­stance throught FMECA
    • Con­trol­ling air­borne con­cen­tra­tions and the con­t­a­m­i­na­tion of prod­uct con­tact sur­faces to val­ues derived from quan­ti­ta­tive risk assess­ments is more appro­pri­ate, regard­less of spe­cific cat­e­gor­i­cal designations
    • Cri­te­ria for select­ing an exter­nal ven­dor for the man­u­fac­ture of HPAPI’s
    • Devel­op­ment of robust process uti­liz­ing plant data systems
    • Doc­u­mented con­tain­ment capa­bil­i­ties: hav­ing the data and being able to explain them
    • Effec­tively scal­ing up potent APIs from clin­i­cal to man­u­fac­tur­ing scale
    • Engi­neer­ing con­trols uti­lized in API plants for HPAPI’s
    • Full overview on Containment
    • Gen­eral SHE aspects: no undue risk for the project
    • Impor­tant to con­sider to design a Con­tain­ment Facility
    • Indus­try move­ment is toward estab­lish­ing compound-​specific health-​based lim­its and per­form­ing risk assess­ments to deter­mine whether seg­re­ga­tion and/​or ded­i­ca­tion may be required
    • Mis­un­der­stand­ings and high risk approaches can lead to delays and sub­stan­tial cost increase
    • Out­sourc­ing of novel com­plex cyto­toxic com­po­nents is challenging
    • Out­sourc­ing: a SME Pharma Perspective
    • Project-​specific tech trans­fer: com­pe­tent and respon­sive part­ners wanted
    • Smart Case stud­ies to avoid obsta­cles and early pitfalls
    • There is typ­i­cally lim­ited process data as well. How do you under­stand the processes and their characteristics?
    • This would include process safety data (calorime­try, tox­i­co­log­i­cal data for intermediates)
    • Tox­i­co­log­i­cal con­cerns in „cross con­t­a­m­i­na­tion” guidelines
    • Will dis­cuss approaches to both and upside and down sides for each)

    Sponsors

    starting: ending: 23.05.2017 Location: , Category:

    Timeline

    Conference START 23.05.2017 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Scarsdale Place Category More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.